Although various promising new therapeutic options are being vigorously pursued [25], acetylcholinesterase inhibitors remain the current front-line therapeutic approach to treatment of mild-to-moderate Alzheimer's disease (AD) [24,26]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.